BioHarvest Sciences Reports Strong Q2 2026 Results Amidst Exciting Developments
In a recent conference call, BioHarvest Sciences announced its second quarter 2026 financial results, showcasing a significant increase in revenue and key developments in the company's programmable plant cell biology. Dr. Zaki Rakib, chairman and chief executive officer of BioHarvest Sciences, welcomed participants to the call, highlighting the company's commitment to innovation and growth.
One of the most notable announcements made during the call was the signing of a CDMO manufacturing and supply agreement with an U.A.E.-based customer. This deal marks another significant validation of BioHarvest Sciences' programmable plant cell biology, which yields highly consistent, bioavailable, and patent-protected precision botanics. The company's AI-driven development and industrial-scale bioreactors have revolutionized plant cell culture production at mass scale.
The agreement relates to a global luxury rare fragrance program, demonstrating the versatility and potential of BioHarvest Sciences' technology. Dr. Rakib emphasized that this announcement showcases the value of the company's programmable plant cell biology and its applications in various industries.
On the financial front, BioHarvest Sciences reported revenues of $8.8 million for the second quarter of 2026, a 3.8% year-over-year increase from $8.5 million for the same period last year. The company's gross profit for the quarter was $5.1 million, or 58% of total revenue, compared to $5.1 million, or 59% of total revenue for the same period last year.
Dr. Rakib attributed the increase in net losses for the second quarter of 2026 to technology development expenditures with CDMO services business unit and investing in new marketing strategies for the products business unit. Net losses totaled $3.7 million, or $0.17 per basic and diluted share, as compared to a net loss of $4.1 million, or $0.24 per basic and diluted share for the same period last year.
Adjusted EBITDA loss for the second quarter of 2026 totaled $1.6 million compared to $1.2 million for the same period last year. Cash and cash equivalents, together with bank deposits as of June 30, 2026, totaled $16 million.
The company's commitment to innovation and growth is evident in its focus on technology development and marketing strategies. As BioHarvest Sciences continues to push the boundaries of plant cell biology, it will be interesting to see how these developments impact the company's future financial performance.
